First patients receive experimental cancer pill targeting specific genetic flaw
NCT ID NCT06908434
Summary
This is the first human study of an experimental pill called GenSci128 for people with advanced solid tumors that have a specific genetic change called TP53 Y220C mutation. The main goals are to find a safe dose and see how the body handles the drug in about 82 participants. This is an early safety study, so determining if the drug effectively controls the cancer is a secondary goal.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS HARBORING A TP53 Y220C MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Hospital ,Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.